

August 4, 2021

Dear Rett Community,

Acadia is pleased to announce that the Phase 3 study of trofinetide, an investigational drug for the treatment of girls and young women 5 to 20 years of age with diagnosed Rett syndrome (LAVENDER™), completed enrollment! We look forward to sharing topline results from this trial by year-end.

Thank you to the International Rett Syndrome Foundation (IRSF) and the entire Rett community who help make this research possible. We appreciate your continued partnership on this journey to find a treatment to address the core symptoms of Rett syndrome.

### **COVID SAFETY PRECAUTIONS**

Your family's health is our priority. We are working closely with clinical sites and study investigators to take all necessary precautions identified through local and national guidance. In addition to protecting the health of study participants and clinical staff, we are also taking appropriate measures to safely and effectively collect patient data to ensure the integrity of study results.

### **FURTHER INFORMATION**

If you have any questions about trofinetide or the clinical trials, please contact us at [medicalinformation@acadiapharm.com](mailto:medicalinformation@acadiapharm.com).

All our best,

The Acadia Rett Team